Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

I've been paying for Mounjaro for more than a year, and have lost a fair bit of weight. Now it's available on the NHS, will I ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the ...

Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming ...